These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 29974604)

  • 21. [Value of European Organisation for Research and Treatment of Cancer score system for predication of immediate postoperative intravesical instillation of pirarubicin after transurethral resection of non-muscle invasive bladder cancer].
    Ding XL; Yang DL; Yan RP; Li ZP; Ye CW; He J; Yu L; He SC; Li HD
    Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):308-312. PubMed ID: 29730921
    [No Abstract]   [Full Text] [Related]  

  • 22. Retrospective analysis of transurethral resection, second-look resection, and long-term chemo-metaphylaxis for superficial bladder cancer: indications and efficacy of a differentiated approach.
    Schulze M; Stotz N; Rassweiler J
    J Endourol; 2007 Dec; 21(12):1533-41. PubMed ID: 18186695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Organ preservation for muscle-invasive bladder cancer by transurethral resection.
    Leibovici D; Kassouf W; Pisters LL; Pettaway CA; Wu X; Dinney CP; Grossman HB
    Urology; 2007 Sep; 70(3):473-6. PubMed ID: 17905099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of immediate instillation combined with regular instillations of pirarubicin for Ta and T1 transitional cell bladder cancer after transurethral resection: a prospective, randomized, multicenter study.
    Li NC; Ye ZQ; Na YQ;
    Chin Med J (Engl); 2013; 126(15):2805-9. PubMed ID: 23924446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy.
    Solsona E; Climent MA; Iborra I; Collado A; Rubio J; Ricós JV; Casanova J; Calatrava A; Monrós JL
    Eur Urol; 2009 Apr; 55(4):911-9. PubMed ID: 18722046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K; Chihara Y; Kondo H; Hirao Y
    Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR.
    Orsola A; Cecchini L; Raventós CX; Trilla E; Planas J; Landolfi S; de Torres I; Morote J
    BJU Int; 2010 Jan; 105(2):202-7. PubMed ID: 19558557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can a second resection be avoided after initial thulium laser endoscopic en bloc resection for non-muscle invasive bladder cancer? A retrospective single-center study of 251 patients.
    Zhou W; Wang W; Wu W; Yan T; Du G; Liu H
    BMC Urol; 2020 Mar; 20(1):30. PubMed ID: 32188429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A second transurethral resection could be not necessary in all high grade non-muscle-invasive bladder tumors].
    Gaya JM; Palou J; Cosentino M; Patiño D; Rodríguez-Faba O; Villavicencio H
    Actas Urol Esp; 2012 Oct; 36(9):539-44. PubMed ID: 22710093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of marker lesion when applying intravesical instillations of IL-2 for non-muscle-invasive bladder cancer comparison of the therapeutic effects in two pilot studies.
    Den Otter W; Van Moorselaar RJ; Jacobs JJ; Haar RT; Koten JW; Dobrowolski Z; Lipczynski W; Pašukonienė V; Characiejus D; Jankevičius F; Eidukevičius R; De Reijke TM
    Anticancer Res; 2013 May; 33(5):2099-105. PubMed ID: 23645761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management and prognosis of transitional cell carcinoma superficial recurrence in muscle-invasive bladder cancer after bladder preservation.
    Pieras E; Palou J; Salvador J; Rosales A; Marcuello E; Villavicencio H
    Eur Urol; 2003 Aug; 44(2):222-5; discussoion 225. PubMed ID: 12875942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intra-arterial chemotherapy for muscle-invasive bladder cancer following transurethral resection.
    Liang S; Zou Q; Han B; Jing Y; Cui D; An X; Gao Y; Hu J; Xia S
    Urol Int; 2015; 94(4):406-11. PubMed ID: 25678415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study.
    Ferro M; Vartolomei MD; Cantiello F; Lucarelli G; Di Stasi SM; Hurle R; Guazzoni G; Busetto GM; De Berardinis E; Damiano R; Perdonà S; Borghesi M; Schiavina R; Almeida GL; Bove P; Lima E; Grimaldi G; Autorino R; Crisan N; Abu Farhan AR; Verze P; Battaglia M; Serretta V; Russo GI; Morgia G; Musi G; de Cobelli O; Mirone V; Shariat SF
    Urol Int; 2018; 101(1):7-15. PubMed ID: 29975950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Conservative treatment of high-risk (T1G3) transitional carcinoma].
    Catanzaro F; Torelli F; Catanzaro M; Cappellano F; Pizzoccaro M; Baruffi M; Sironi D; Pozzoli GL
    Arch Ital Urol Androl; 1996 Feb; 68(1):21-4. PubMed ID: 8664915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of bladder preservation therapy on survival in patients with muscle-invasive bladder cancer.
    Özaydın Ş; Ataş E; Karadurmuş N; Emirzeoğlu L; Arpacı F
    Arch Esp Urol; 2020 Jan; 73(1):41-46. PubMed ID: 31950922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of superficial transitional cell bladder carcinoma. Long-term results of trial comparing transurethral resection alone and adjuvant chemotherapy with Doxorubicin].
    Milonas D; Mickevicius J; Mickevicius R; Motiejūnas A; Sukys D; Gudinaviciene I
    Medicina (Kaunas); 2002; 38 Suppl 1():79-83. PubMed ID: 12556642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
    Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic factors in invasive bladder carcinoma treated by combined modality protocol (organ-sparing approach).
    Matos T; Cufer T; Cervek J; Bornstnar S; Kragelj B; Zumer-Pregelj M
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):403-9. PubMed ID: 10661347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A re-staging transurethral resection predicts early progression of superficial bladder cancer.
    Herr HW; Donat SM
    BJU Int; 2006 Jun; 97(6):1194-8. PubMed ID: 16566813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repeated transurethral resection and intravesical BCG for extensive superficial bladder tumors.
    Ozen H; Ekici S; Uygur MC; Akbal C; Sahin A
    J Endourol; 2001 Oct; 15(8):863-7. PubMed ID: 11724131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.